<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite advances in contemporary chemotherapeutic strategies, long-term survival still remains elusive for patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A better understanding of the molecular markers of drug sensitivity to match therapy with patient is needed to improve clinical outcomes </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we used in vitro drug sensitivity data from the NCI-60 cell lines together with their Affymetrix microarray data to develop a gene expression signature to predict sensitivity to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>To validate our <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> sensitivity signature, patient-derived <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> explants (PDCCE) were developed in nonobese diabetic/severe combined immunodeficient (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e>/<z:mp ids='MP_0002536'>SCID</z:mp>) mice from resected human <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Analysis of gene expression profiles found similarities between the PDCCEs and their parental human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, suggesting their utility to study drug sensitivity in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> sensitivity signature was then validated in vivo with response data from 14 PDCCEs treated with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and was found to have an accuracy of 92.9% (sensitivity = 87.5%; specificity = 100%) </plain></SENT>
<SENT sid="6" pm="."><plain>Our findings suggest that PDCCEs can be a novel source to study drug sensitivity in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, genomic-based analysis has the potential to be incorporated into future strategies to optimize individual therapy for patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
</text></document>